BRPI1007186A2 - composto, composição farmacêutica, e, uso de um composto - Google Patents

composto, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI1007186A2
BRPI1007186A2 BRPI1007186A BRPI1007186A BRPI1007186A2 BR PI1007186 A2 BRPI1007186 A2 BR PI1007186A2 BR PI1007186 A BRPI1007186 A BR PI1007186A BR PI1007186 A BRPI1007186 A BR PI1007186A BR PI1007186 A2 BRPI1007186 A2 BR PI1007186A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI1007186A
Other languages
English (en)
Inventor
Daigo Asano
Katsuyoshi Nakajima
Kazumasa Aoki
Kiyoshi Oizumi
Osamu Kanno
Ryoichi Tanaka
Shimpei Hirano
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI1007186A2 publication Critical patent/BRPI1007186A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
BRPI1007186A 2009-01-19 2010-01-12 composto, composição farmacêutica, e, uso de um composto BRPI1007186A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009008635 2009-01-19
PCT/JP2010/050221 WO2010082563A1 (ja) 2009-01-19 2010-01-12 ヘテロ原子を有する環状化合物

Publications (1)

Publication Number Publication Date
BRPI1007186A2 true BRPI1007186A2 (pt) 2016-02-23

Family

ID=42339816

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007186A BRPI1007186A2 (pt) 2009-01-19 2010-01-12 composto, composição farmacêutica, e, uso de um composto

Country Status (18)

Country Link
US (1) US8685981B2 (pt)
EP (1) EP2380878B1 (pt)
JP (1) JP5630868B2 (pt)
KR (1) KR20110110183A (pt)
CN (1) CN102325754B (pt)
AU (1) AU2010205239B2 (pt)
BR (1) BRPI1007186A2 (pt)
CA (1) CA2749114C (pt)
CO (1) CO6420338A2 (pt)
ES (1) ES2431824T3 (pt)
IL (1) IL213997A0 (pt)
MX (1) MX2011007543A (pt)
NZ (1) NZ593996A (pt)
RU (1) RU2011134637A (pt)
SG (1) SG172800A1 (pt)
TW (1) TW201030003A (pt)
WO (1) WO2010082563A1 (pt)
ZA (1) ZA201104717B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312321A1 (en) * 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
KR20150085538A (ko) 2012-11-20 2015-07-23 에프. 호프만-라 로슈 아게 치환된 1,6-나프티리딘
CA2911156A1 (en) * 2013-05-03 2014-11-06 F. Hoffmann-La Roche Ag Neurogenesis-stimulating isoquinoline derivatives
CN104788450A (zh) * 2015-04-23 2015-07-22 湖南华腾制药有限公司 一种吡啶并哌嗪衍生物的制备方法
IL300572A (en) 2018-02-13 2023-04-01 Gilead Sciences Inc PD–1/PD–L1 inhibitors
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN115181091A (zh) * 2022-06-21 2022-10-14 江苏联环药业股份有限公司 一种贝他斯汀的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403757B (en) 1994-12-28 2000-09-01 Takeda Chemical Industries Ltd Optically active benzothiepin derivative, its preparation and use
JPH09188665A (ja) 1996-01-05 1997-07-22 Kyorin Pharmaceut Co Ltd 新規置換n−キノリルアントラニル酸誘導体及びその製造法
MXPA03010679A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
WO2002100405A1 (en) * 2001-06-11 2002-12-19 Vertex Pharmaceuticals Incorporated Isoquinoline inhibitors of p38
US20050096322A1 (en) 2002-03-01 2005-05-05 Susumu Igarashi Nitrogen-containing heterocyclic compound
JP4385620B2 (ja) * 2002-03-01 2009-12-16 アステラス製薬株式会社 含窒素複素環化合物
US7282506B2 (en) * 2004-08-03 2007-10-16 Serenex, Inc. 2,8-disubstituted naphthyridine derivatives
GB0516723D0 (en) * 2005-08-15 2005-09-21 Novartis Ag Organic compounds
JP2007131617A (ja) 2005-10-11 2007-05-31 Sankyo Co Ltd チエノピリジン誘導体を含有する医薬

Also Published As

Publication number Publication date
CA2749114A1 (en) 2010-07-22
TW201030003A (en) 2010-08-16
EP2380878A4 (en) 2012-06-13
NZ593996A (en) 2012-10-26
ES2431824T3 (es) 2013-11-28
ZA201104717B (en) 2012-03-28
CO6420338A2 (es) 2012-04-16
JP5630868B2 (ja) 2014-11-26
IL213997A0 (en) 2011-08-31
SG172800A1 (en) 2011-08-29
EP2380878B1 (en) 2013-08-14
CN102325754A (zh) 2012-01-18
MX2011007543A (es) 2011-09-06
AU2010205239A1 (en) 2011-08-04
KR20110110183A (ko) 2011-10-06
JPWO2010082563A1 (ja) 2012-07-05
CA2749114C (en) 2013-12-17
US20110269746A1 (en) 2011-11-03
WO2010082563A1 (ja) 2010-07-22
US8685981B2 (en) 2014-04-01
CN102325754B (zh) 2014-03-12
RU2011134637A (ru) 2013-02-27
EP2380878A1 (en) 2011-10-26
AU2010205239B2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI0918360A2 (pt) composto, composição farmacêutica e usos de um composto
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0915134A2 (pt) composto, e, uso de um composto
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI1007186A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0919165A2 (pt) composição farmacêutica,e, uso de um composto
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.